Hous­ton's Avance Bio­sciences an­nounces an­oth­er ex­pan­sion, this time fo­cused on cell-based as­says

With its foot in the door of biotech’s bur­geon­ing cell and gene ther­a­py in­dus­try, Hous­ton’s Avance Bio­sciences is tak­ing ad­van­tage of what it says is a “rapid­ly grow­ing” de­mand for its ser­vices.

The CRO an­nounced Tues­day that it will add 5,500 square feet to its Texas head­quar­ters to fo­cus on cell-based as­say ser­vices.

“We take a part­ner­ship ap­proach with our clients and that means an ex­tend­ed re­la­tion­ship; from dis­cov­ery to de­vel­op­ment to clin­i­cal test­ing and on to man­u­fac­tur­ing,” Avance CEO Xuen­ing Huang said in a state­ment. “Our most re­cent ex­pan­sions will en­sure that we can keep pace with our cus­tomer’s in­creased needs when ramp­ing up de­vel­op­ment and man­u­fac­tur­ing ac­tiv­i­ties.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.